{"id":40983,"date":"2025-09-09T14:02:03","date_gmt":"2025-09-09T06:02:03","guid":{"rendered":"https:\/\/flcube.com\/?p=40983"},"modified":"2025-09-09T14:02:04","modified_gmt":"2025-09-09T06:02:04","slug":"sirnaomics-secures-hk138-m-investment-from-bloomage-biotech-expanding-oncology-and-aesthetic-pipelines","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40983","title":{"rendered":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines"},"content":{"rendered":"\n<p>Sirnaomics Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2257:HKG\">HKG: 2257<\/a>) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (<a href=\"https:\/\/www.google.com\/finance\/quote\/688363:SHA\">SHA: 688363<\/a>). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-key-deal-highlights\">Key Deal Highlights<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investment Size<\/strong> \u2013 HK$138\u202fmillion in placed shares at HK$12 each.<\/li>\n\n\n\n<li><strong>Equity Stake<\/strong> \u2013 Bloomage will own about 9.44\u202f% of Sirnaomics post\u2011transaction.<\/li>\n\n\n\n<li><strong>Strategic Alignment<\/strong> \u2013 Enables Sirnaomics to reallocate internal resources toward oncology and autoimmune disease pipelines.<\/li>\n\n\n\n<li><strong>Value Creation<\/strong> \u2013 Leverages Bloomage\u2019s expertise to enhance Sirnaomics\u2019 medical\u2011aesthetics portfolio.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-collaborative-innovation\">Collaborative Innovation<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Synergy<\/strong> \u2013 Sirnaomics\u2019 proprietary <strong>PNP (Peptide Nanoparticle)<\/strong> and <strong>GalAhead<\/strong> delivery platforms will be combined with Bloomage\u2019s research in hyaluronic acid and biologics.<\/li>\n\n\n\n<li><strong>Product Roadmap<\/strong> \u2013 Joint development of a new generation of precision\u2011delivery therapeutics that target both cancer and autoimmune indications.<\/li>\n\n\n\n<li><strong>Resource Allocation<\/strong> \u2013 Funding will accelerate preclinical and clinical milestones while expanding the company\u2019s product breadth.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Focus<\/strong> \u2013 The infusion of capital supports accelerated progression of Sirnaomics\u2019 oncology candidates through Phase\u202f2\/3 studies.<\/li>\n\n\n\n<li><strong>Autoimmune Expansion<\/strong> \u2013 Enhanced pipeline depth positions the company to capture a larger share of the growing autoimmune therapeutics market.<\/li>\n\n\n\n<li><strong>Aesthetic Synergy<\/strong> \u2013 Bloomage\u2019s established market presence in medical aesthetics provides an immediate commercial channel for Sirnaomics\u2019 novel delivery technologies.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-forward-look\">Forward\u2011Look<\/h4>\n\n\n\n<p>Sirnaomics plans to deploy the investment toward key clinical programs, while Bloomage Biotech will provide strategic guidance and market access. Both firms anticipate that the partnership will unlock significant long\u2011term shareholder value and accelerate the translation of cutting\u2011edge delivery platforms into clinically relevant therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40984,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2276,845,64,2275,440],"class_list":["post-40983","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bloomage-biotech","tag-hkg-2257","tag-rnai-aso","tag-sha-688363","tag-sirnaomics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40983\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines\" \/>\n<meta property=\"og:description\" content=\"Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40983\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T06:02:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-09T06:02:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines\",\"datePublished\":\"2025-09-09T06:02:03+00:00\",\"dateModified\":\"2025-09-09T06:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0907.webp\",\"keywords\":[\"Bloomage Biotech\",\"HKG: 2257\",\"RNAi \\\/ ASO\",\"SHA: 688363\",\"Sirnaomics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40983#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40983\",\"name\":\"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0907.webp\",\"datePublished\":\"2025-09-09T06:02:03+00:00\",\"dateModified\":\"2025-09-09T06:02:04+00:00\",\"description\":\"Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40983\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0907.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0907.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40983#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines - Insight, China&#039;s Pharmaceutical Industry","description":"Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40983","og_locale":"en_US","og_type":"article","og_title":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines","og_description":"Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.","og_url":"https:\/\/flcube.com\/?p=40983","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-09T06:02:03+00:00","article_modified_time":"2025-09-09T06:02:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40983#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40983"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines","datePublished":"2025-09-09T06:02:03+00:00","dateModified":"2025-09-09T06:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40983"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40983#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp","keywords":["Bloomage Biotech","HKG: 2257","RNAi \/ ASO","SHA: 688363","Sirnaomics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40983#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40983","url":"https:\/\/flcube.com\/?p=40983","name":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40983#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40983#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp","datePublished":"2025-09-09T06:02:03+00:00","dateModified":"2025-09-09T06:02:04+00:00","description":"Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong\u202fKong) Limited, a wholly\u2011owned subsidiary of Bloomage Biotech (SHA: 688363). Bloomage will subscribe to Sirnaomics\u2019 placed shares at HK$12 per share, totaling approximately HK$138\u202fmillion and acquiring roughly 9.44\u202f% of Sirnaomics\u2019 issued share capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40983#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40983"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40983#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp","width":1080,"height":608,"caption":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40983#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sirnaomics Secures HK$138\u202fM Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0907.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40983"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40983\/revisions"}],"predecessor-version":[{"id":40985,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40983\/revisions\/40985"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40984"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}